The Pipeline, page-21

Remember about genetech with Insulin and Trastuzumab. I think SPL could reach this level, big boys would be playing on. At last SPL would give up, and come to one of the big boys team. But too eager to see phase 1 results, please dont let me down. From my clinical experience, the hair loss and vomiting using docetaxel is very common, nearly 90% patients, and if true DEP™ docetaxel is amazing.
In case DEP™ docetaxel is successful, next step is Her2-DEP docetaxel, who know could replace the breast cancer resection at first-line choice. That will change the whole oncology.